Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome Therapeutics, Inc. (AXSM): Are Hedge Funds Done Buying?
04:24pm, Monday, 15'th Jun 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Axsome Therapeutics Inc (NASDAQ:AXSM) Shares Sold by Sowell Financial Services LLC
06:28am, Wednesday, 10'th Jun 2020
Sowell Financial Services LLC cut its holdings in shares of Axsome Therapeutics Inc (NASDAQ:AXSM) by 48.8% during the first quarter, Holdings Channel.com reports. The institutional investor owned 844
State Street Corp Has $38.91 Million Stake in Axsome Therapeutics Inc (NASDAQ:AXSM)
05:08am, Wednesday, 10'th Jun 2020
State Street Corp increased its stake in shares of Axsome Therapeutics Inc (NASDAQ:AXSM) by 5.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 661,315 shares
Why Is Axsome (AXSM) Down 15.7% Since Last Earnings Report?
03:30pm, Sunday, 07'th Jun 2020
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Rockefeller Capital Management L.P. Makes New $138,000 Investment in Axsome Therapeutics Inc (NASDAQ:AXSM)
07:32am, Sunday, 07'th Jun 2020
Rockefeller Capital Management L.P. bought a new position in shares of Axsome Therapeutics Inc (NASDAQ:AXSM) during the 1st quarter, according to its most recent disclosure with the SEC. The fund boug
Edited Transcript of AXSM earnings conference call or presentation 8-May-20 12:00pm GMT
10:27pm, Thursday, 04'th Jun 2020
Q1 2020 Axsome Therapeutics Inc Earnings Call
Axsome Therapeutics to Present at Upcoming Investor Conferences
11:00am, Thursday, 04'th Jun 2020
Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat. A live webcast and archive of the William Blair event can be viewed on the "Webcasts & Presentat
Jazz Pharmaceuticals: Pandemic Leaves The Leading Drug In A Catch 22 (NASDAQ:JAZZ)
04:56pm, Monday, 01'st Jun 2020
As the pandemic fears squeeze the new patient enrollments for Xyrem, JAZZ has downgraded the revenue guidance. While the economic downturn stifles the revenue g
Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that data from the GEMINI Phase 3
Is Axsome Therapeutics a Buy?
04:57pm, Tuesday, 26'th May 2020
The pharmaceutical company appears poised to earn multiple regulatory approvals in 2021. But has too much anticipated success already been priced into its shares?
Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually
11:00am, Tuesday, 26'th May 2020
Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the Company’s 2020 Annual Meeti
Better Buy: Biogen vs. Axsome Therapeutics
11:36am, Saturday, 23'rd May 2020
One biotech has been big long-time winner, the other is a promising up-and-comer with no revenue -- yet. But picking an investment is always a bet on the future.
What's Behind Axsome Therapeutics' Miracle Pipeline?
10:04am, Tuesday, 19'th May 2020
Just what exactly is going on with this company, which has had success in nearly every single clinical trial it initiated in recent years?
Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses
03:56pm, Monday, 11'th May 2020
Axsome (AXSM) incurs a wider loss in the first quarter of 2020. However, the company is advancing well with the NDA for AXS-05 and AXS-07.
